Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Refractory Multiple Myeloma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma.

ONC-206 is under clinical development by Chimerix and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.

Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase II for Non-Small Cell Lung Cancer.

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Immunological Disorders.

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).